Atomo Diagnostics Boosts FY26 Revenue 40% with Expanding HIV and OEM Sales

Revenue Growth Fueled by HIV Self-Test and OEM Expansion

Atomo Diagnostics (ASX:AT1) closed FY26 with a 40% jump in revenue to $5.3 million, underpinned by a 33% increase in Australian pharmacies selling its HIV self-test and a growing OEM customer base for its Pascal cassettes. Quarterly revenue hit $2.3 million, including $1.6 million from HIV sales and $670,000 from OEM orders, reflecting strong momentum in established channels.

The company secured over $1.5 million in new sales orders during Q4 and anticipates formalising long-term supply agreements with two new OEM customers in Canada and the UK during Q1 FY27. This expansion follows earlier wins linked to Lumos Diagnostics’ FebriDx FDA CLIA waiver, which unlocked significant US market potential for Pascal cassettes.

Pharmacy Network Growth in Australia and New Zealand

Atomo’s pharmacy footprint in Australia grew by 49 outlets this quarter to 190, with management targeting a sixfold expansion over the next three years. New Zealand also saw progress, activating 70 pharmacies since its FY25 launch and aiming for an eightfold increase in the same timeframe. CDC, a major pharmacy wholesaler, began placing orders in New Zealand this quarter, supporting the company’s international growth ambitions.

Advancing New Test Developments and Clinical Trials

Beyond HIV, Atomo is progressing its syphilis rapid test, designed to distinguish active from prior infections; a capability lacking in current market offerings. Product development and initial verification are complete, with technology transfer for manufacturing underway. Clinical trials are scheduled to commence mid FY27, supported by positive preliminary data demonstrating market-leading sensitivity above 85% for active syphilis detection.

The company is also advancing its Atomo Liver function test, focusing on monitoring patients prescribed at-risk drugs. Engagement with pharmaceutical partners, clinical leaders, and public health stakeholders is underway to define priority use cases and explore funding opportunities, particularly given the global public health burden of fatty liver disease.

Manufacturing Capacity and Operational Enhancements

Atomo has successfully relocated and qualified its second-generation blister machine at a Sydney facility, integrating it into its Quality Management System. This upgrade, combined with high-cavitation mould tooling under qualification, is expected to increase Pascal production volumes and improve margins, particularly for OEM supply. These manufacturing advances align with the company’s strategy to scale efficiently as demand grows.

Financial Discipline and Cash Position

The company reported cash receipts of $3.8 million in Q4, including $1 million from customers, $165,000 from the Syphilis CRC-P grant, and approximately $2.7 million from placement funds net of transaction costs. Operating expenses were managed at $1.4 million for the quarter, excluding government grants and R&D rebates that further support the bottom line by more than 15%. Atomo ended the quarter debt-free with $3.7 million in cash, positioning it to fund ongoing development and commercialisation activities.